薬剤性腎障害（Toxicology）

Urinary liver-type fatty acid-binding protein in two dogs with acquired Fanconi syndrome: A case report.

Urinary L-type fatty acid-binding protein is a predictor of cisplatin-induced acute kidney injury.

Clinical Utility of a Biomarker to Detect Contrast-Induced Acute Kidney Injury during Percutaneous Cardiovascular Procedures.

Changing trends in lipid profile and biomarkers of renal function and bone metabolism before and after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study.

Early changes in tubular dysfunction markers and phosphorus metabolism regulators as a result of switching from entecavir to tenofovir alafenamide fumarate nucleoside analog therapy for chronic hepatitis B patients.

The influence of renal function by ibuprofen treatment for patent ductus arteriosus in extremely low-birth-weight infants.

Utility of urinary liver-type fatty acid-binding protein as a predictor of renal dysfunction in Japanese patients with HIV receiving tenofovir disoproxil fumarate with low urinary β2 microglobulin levels: a retrospective observational study.

Biomarkers of drug-induced kidney toxicity.

The ischemic/nephrotoxic Acute Kidney Injury and the use of renal biomarkers in clinical practice.

The potential use of biomarkers in predicting contrast-induced acute kidney injury.

Renoprotective effect of the xanthine oxidoreductase inhibitor, Topiroxostat,on Adenine-Induced Renal Injury.

Response of urinary liver-type fatty acid-binding protein to contrast media administration has a potential to predict one-year renal outcome in patients with ischemic heart disease.

Human liver-type fatty acid-binding protein protects against tubulointerstitial injury in aldosterone-induced renal injury.

Urine liver-type fatty acid-binding protein and kidney injury molecule-1 in HIV-infected patients receiving combined antiretroviral treatment based on tenofovir.

Remote Ischemic Pre-Conditioning Alleviates ContrastInduced Acute Kidney Injury in Patients With Moderate Chronic Kidney Disease.

Urinary liver-type fatty acid-binding protein level as a predictive biomarker of contrast-induced acute kidney injury.

Renal liver-type fatty acid binding protein (L-FABP) attenuates acute kidney injury in aristolochic acid nephrotoxicity.

Urinary excretion of liver type fatty acid binding protein accurately reflects the degree of tubulointerstitial damage.

Monitoring of urinary L-type fatty acid-binding protein predicts histological severity of acute kidney injury.

Urinary human L-FABP is a potential biomarker to predict COX-inhibitor-induced renal injury.

Renal L-type fatty acid-binding protein mediates the bezafibrate reduction of cisplatin-induced acute kidney injury.

L-Type Fatty Acid Binding Protein Transgenic Mouse as a Novel Tool to Explore Cytotoxicity to Renal Proximal Tubules.

A role of liver fatty acid-binding protein in cisplatin-induced acute renal failure.

Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy.